Pharmaceutical compositions comprising phosphate-binding...

Details Pharmaceutical compositions comprising phosphate-binding... Pharmaceutical compositions comprising phosphate-binding...

2011-06-21

2011-06-21

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Monomer contains oxygen

C424S078350, C424S501000, C528S398000

Reexamination Certificate

active

07964182

ABSTRACT:
The present invention discloses pharmaceutical composition comprising phosphate binding polymers such as Sevelamer carbonate substantially free of monovalent anion other than bicarbonate anion. Particularly, monovalent anion content is less than about 0.05% (w/w). Disclosed are compositions comprising wet granulated Sevelamer carbonate free of added metal ions and/or added monovalent anion source.

REFERENCES:
patent: 4605701 (1986-08-01), Harada et al.
patent: 5275824 (1994-01-01), Carli et al.
patent: 5490987 (1996-02-01), Shen et al.
patent: 5496545 (1996-03-01), Holmes-Farley et al.
patent: 6083495 (2000-07-01), Holmes-Farley et al.
patent: 6121411 (2000-09-01), Satori et al.
patent: 6362266 (2002-03-01), Buchholz et al.
patent: 6383518 (2002-05-01), Matsuda et al.
patent: 6525113 (2003-02-01), Klix et al.
patent: 6600011 (2003-07-01), McDonnell et al.
patent: 6696087 (2004-02-01), Matsuda et al.
patent: 6733780 (2004-05-01), Tyler et al.
patent: 6756364 (2004-06-01), Barbier et al.
patent: 7229613 (2007-06-01), Burke et al.
patent: 7381424 (2008-06-01), MacGregor
patent: 7388056 (2008-06-01), Gopalkrishna et al.
patent: 7749536 (2010-07-01), Hrakovsky et al.
patent: 2002/0054903 (2002-05-01), Tyler et al.
patent: 2002/0119193 (2002-08-01), Le et al.
patent: 2005/0131138 (2005-06-01), Connor et al.
patent: 2006/0251614 (2006-11-01), Bhagat et al.
patent: 2007/0027213 (2007-02-01), Oberegger et al.
patent: 2007/0110706 (2007-05-01), Connor et al.
patent: 2007/0190135 (2007-08-01), Matsuda et al.
patent: 2009/0280178 (2009-11-01), Hedge et al.
patent: 2010/0008988 (2010-01-01), Mehta et al.
patent: 2010/0137542 (2010-06-01), Jobdevairakkam et al.
patent: 1304104 (2003-04-01), None
patent: 1818048 (2007-08-01), None
patent: 142/MUM/2009 (2009-01-01), None
patent: WO0121211 (2001-03-01), None
patent: WO2005041900 (2005-05-01), None
patent: WO2007094779 (2007-03-01), None
patent: WO2009156014 (2009-12-01), None
“(logo) RENVELA® (Sevelamer Carbonate),” label (downloaded from www.fda.gov/cder/foi/label/2007/022127lbl.pdf) Food and Drug Administration (2007).
Ritz, E., et al., “Role of Sodium Intake in the Progression of Chronic Kidney Disease,” Journal of Renal Nutrition 2009, 19 (1): 61-2, (2009).
Chertow, G.M., et al., “The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic vascular disease in hemodialysis patients,” American Journal of Nephrology, 23(5): 307-314 (2003).
Mazzeo, J.R. et al., “A Phosphate Binding Assay for Sevelamer Hydrochloride by Ion Chromatography,” J. Pharm. Biomed. Anal. (1999) 19, pp. 911-915.
“(logo) RENEGAL Tablets (sevelamer hydrochloride) 400 and 800 mg,” Package insert (downloaded from http://www.fda.gov/cder/foi/label/2000/21179lbl.pdf), Food and Drug Administration (2000).
Schulz, W, “Sevelamer Hydrochloride,” Taegliche Praxis, XX, (2001) vol. 42, No. 3, pp. 621-626.

Affiliated with

Also associated with

Rating

Pharmaceutical compositions comprising phosphate-binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions comprising phosphate-binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising phosphate-binding... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2737938